BamSEC and AlphaSense Join Forces
Learn More

Vaxcyte Inc. – Material Contracts

NASDAQ: PCVX    
Share price (9/11/26): $59.47    
Market cap (9/11/26): $8.849 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 48 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Mint Development and Manufacturing Services Agreement
12/34/56
EX-10.11
from 10-K 4 pages I Am Pleased to Offer You a Position With Vaxcyte, Inc. (The “Company”) as Senior Vice President, Commercial Manufacturing & Supply Chain Reporting to Me, on the Following Terms (Collectively, the “Agreement”). if You Accept Our Offer, Your First Day of Employment Will Be October 1, 2021, or as Otherwise Mutually Agreed (“Start Date”)
12/34/56
EX-10.1
from 8-K 2 pages First Amendment to Executive Change in Control and Severance Agreement
12/34/56
EX-10.1
from 10-Q 33 pages Master Services Agreement
12/34/56
EX-10.2
from 10-Q 6 pages Vaxcyte, Inc. Performance Contingent Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 7 pages Vaxcyte, Inc. Psu Award Grant Notice
12/34/56
EX-10.22
from 10-K 74 pages Amended and Restated Lease Agreement
12/34/56
EX-10.27
from 10-K 10 pages Vaxcyte, Inc. Rsu Award Grant Notice – NON-U.S
12/34/56
EX-10.26
from 10-K 10 pages Vaxcyte, Inc. Stock Option Grant Notice – NON-U.S
12/34/56
EX-10.23
from 10-K 5 pages First Amendment to Lease
12/34/56
EX-10.21
from 10-K 3 pages Amendment No. 1 to the License Agreement Between Columbia Sutrovax, Inc. and the Regents of the University of California for Ucsd Case No. Sd2012-011
12/34/56
EX-10.19
from 10-K 44 pages Manufacturing Rights Agreement
12/34/56
EX-10.14
from 10-K 51 pages Pre-Commercial Services and Commercial Manufacturing Supply Agreement
12/34/56
EX-10.12
from 10-K 34 pages Master Services Agreement for Drug Product Development and Manufacturing
12/34/56
EX-10.3
from 10-Q 10 pages Third Amendment to Amended and Restated Sutrovax Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Consent to Assignment and First Amendment
12/34/56
EX-10.1
from 10-Q 67 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Assignment and Assumption of Lease
12/34/56
EX-10.2
from 10-Q 6 pages Vaxcyte, Inc. Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 30 pages Vaxcyte, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: June 4, 2020 Approved by the Stockholders: June 4, 2020
12/34/56
EX-10
from 10-Q 28 pages Development and Manufacturing Services Agreement
12/34/56